Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 59

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 59
---
   |     |           |       - |   |
| Common stock, $0.001 par value per share; 250,000,000                                                                                    
 shares authorized, 60,729,100 shares issued and outstanding; 250,000,000 shares authorized and 63,854,100 shares issued and outstanding, 
 pro forma                                                                                                                                |     | $             |      61 |   |     |           |      64 |   |
| Additional paid-in capital                                                                                                               |     | $             |  31,741 |   |     |           |  36,138 |   |
| Accumulated deficit                                                                                                                      |     | $             | (13,703 | ) |     |           | (13,703 | ) |
| Total shareholders’ equity                                                                                                               |     | $             |  18,099 |   |     |           |  22,499 |   |
| Total capitalization                                                                                                                     |     | $             |  18,099 |   |     |           |  22,499 |   |

The number of the Common Stock to be issued and
outstanding immediately after this offering as shown above assumes that all of the Common Stock offered hereby are sold, and is based
on 60,729,100 Common Stock issued and outstanding as of the date of this prospectus. This number excludes:

| ● | 4,270,000 Common Stock                                                                                                                
 issuable upon the exercise of options issued to directors, employees and consultants under our incentive option plan outstanding      
 as of such date, with the average exercise prices at $0.29 per share, of which options to purchase 4,022,500 Common Stock were vested 
 as of such date;                                                                                                                      |

| ● | 2,930,000 Common Stock                                                          
 reserved for future issuance under our 2021 Global Share Incentive Plan (2021). |

| ● | 6,372,265 Common Stock                                                                                                                
 issuable upon the exercise of our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 
 31, 2026;                                                                                                                             |

<div align='center'>33

DILUTION</div>

If you purchase shares underlying the Units
offered by the Company in this Primary Offering, you may experience dilution to the extent of the difference between the price per share
you pay in this Primary Offering and the net tangible book value per share of our Common Stock immediately after this offering.